Navigation Links
Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Date:6/4/2011

gating the potential predictive benefit of CTCs in metastatic prostate cancer clinical trials as there are limited ways of assessing therapeutic benefit in this disease, especially when it has metastasized to the bone."

Additional studies are underway to further validate CTCs as a surrogate endpoint in metastatic prostate cancer studies.

Study Design

The CTC analysis was conducted to determine if CTCs could be used as a surrogate for overall survival.  It was performed in 900 of the 1195 enrolled study patients with metastatic castration-resistant prostate cancer post-docetaxel being treated with either abiraterone acetate plus prednisone or placebo plus prednisone.  CTCs were counted (cells/7.5 mL) along with other biomarkers including PSA, LDH, hemoglobin, alkaline phosphatase at screening and baseline and post-baseline at four, eight and 12 weeks. Analyses were conducted for these biomarkers individually and collectively.

Veridex provided product support for the study. 

Dr. Howard Scher has provided consulting services to the company. 

Additional Data Presented at ASCO Substantiates In Vitro Diagnostic Use of CELLSEARCH® CTC Test

An independent study investigating the in vitro diagnostic use of CTC testing found that the number of CTCs in the blood may help physicians more reliably assess treatment benefit for patients with metastatic breast cancer.  The study, a large-scale retrospective analysis using blinded data to create a pooled dataset of 841 patients from cancer centers around the world, found that CTC count at or above the threshold of five was reliably associated with disease progression.  Further, the predictive value of CTCs was not affected by treatment type (chemotherapy, endocrine therapy, biologic therapy), tumor type (hormone receptor positive/negative, HER2 positive/negative),
'/>"/>

SOURCE Veridex, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
2. American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA
3. American Stroke Association Late-Breaking Science Report: Antiplatelet Drug May Be Better Than Aspirin in Preventing Recurrent Strokes
4. American Heart Association Late-Breaking Clinical Trial Report: New Reversible Oral Drug Reduces Cardiac Events in Primary PCI Patients
5. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
6. MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
7. MAP Pharmaceuticals Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
8. Impulse Dynamics Announces Pivotal Results at the American College of Cardiology Annual Meeting Late-Breaking Session
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. Atritech to Participate in Late-Breaking Clinical Trial Presentation at American College of Cardiology Meeting
11. Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... YORK and LONDON , ...   FDNA Inc. ( http://www.fdna.com ) and ... that they have partnered to offer, for the first ... through FDNA,s solutions. FDNA, developer of the ... integrate LMD,s award-winning collection into Face2Gene [ TM ...
(Date:8/26/2014)... -- Based on its recent analysis of the breast imaging solutions ... North American Frost & Sullivan Award for Technology Innovation Leadership. ... solutions for the early detection of breast cancer. Over the ... solutions and has expanded its global reach to cover ... , Asia and Australia ...
(Date:8/26/2014)... , Aug. 26, 2014 Novira Therapeutics, ... for curative treatment of chronic hepatitis B virus (HBV) ... M.D., F.A.C.P., was appointed the Chair of its Scientific ... function as a Senior Advisor to the Company.  ... our SAB as Chair," said Christian Schade , ...
Breaking Medicine Technology:FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 2FDNA Partners with London Medical Databases (LMD) to Provide Long-Awaited Online Access to Leading Dysmorphology Database 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 2Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 4Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 5Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 3Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board 4
... 2011 Advanced Cell Diagnostics (ACD), a technological ... provider for biomedical image and data analysis, announce ... applications that will enable researchers to accurately quantify ... clinical specimen. The partnership will build on ACD,s ...
... 31, 2011 Vanda Pharmaceuticals Inc. (Nasdaq: ... Phase IIb/III clinical trial of tasimelteon in patients with ... begin during the second half of 2011.  Tasimelteon is ... the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind ...
Cached Medicine Technology:Advanced Cell Diagnostics and Definiens Partner to Develop Tool for Quantitative Biomarker Analysis 2Advanced Cell Diagnostics and Definiens Partner to Develop Tool for Quantitative Biomarker Analysis 3Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression 2Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression 3Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression 4
(Date:8/27/2014)... 2014 The use of ESAs to ... and may eliminate the need for blood transfusion and ... AllMed webinar, Dr. Zanhua Yi, board certified in hematology, ... medical necessity of erythropoiesis-stimulating agents (ESAs) in the treatment ... U.S. Food and Drug Administration (FDA) has approved three ...
(Date:8/27/2014)... Janice Holly Booth didn’t choose to travel ... her on an adventure outing to southern Utah where she’d ... harnesses and rappelling into mysterious, dark and potentially dangerous canyons. ... not my last,” she says. “I travelled alone for more ... edge, and experienced first-hand the kind of fear that keeps ...
(Date:8/27/2014)... The Connecticut Community for Addiction Recovery (CCAR) ... 2014, from 10:00 AM – 2:00 PM in Bushnell Park ... participants across the state to show their support for recovery ... state capitol. , Recovery Walks! is a celebration for the ... and other drugs as well as their families, friends, and ...
(Date:8/26/2014)... August 27, 2014 Hearing aids ... be hard for plan holders to determine what their hearing ... participating in several additional health plans and has published benefit ... assistance page . , The following is a list ... a participating provider: , NYSHIP/ NYS Empire Plan - Hearing ...
(Date:8/26/2014)... Emerging and established leaders who want to ... they serve – which includes their subordinates – should ... and read his latest must-read blog post titled ... , “Leadership is not a static role ... assumed,” commented Per Wickstrom, who blogs regularly on a ...
Breaking Medicine News(10 mins):Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 2Health News:AllMed Webinar Helps Health Plans Determine Medical Necessity Of ESAs In The Treatment Of Chronic Kidney Disease 3Health News:Best-selling Author Janice Holly Booth Offers Tips to Navigating Fear and Living a Fuller Life 2Health News:The CT Community for Addiction Recovery to Proudly Host 15th Annual Recovery Walks! 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 2Health News:East End Hearing of Long Island Now Participating in Many Local Health Plans 3Health News:Per Wickstrom’s Latest Blog Post Provides 10 Tips to Help Leaders Maintain their Edge 2
... Across Nation Using Caregiverlist.com to Find Quality ... ... the nation,s online,destination dedicated to connecting seniors with quality senior care,choices, ... senior,in-home care services as the caregiving recruitment source for the,industry. Nearly ...
... are turning their attention to the normal cells that ... tumor growth might be stopped at the earliest opportunity. ... come from can provide critical insight into how cancers ... and Cancer Biology at Duke University Medical Center. "This ...
... aggressive childhood brain tumor known as medulloblastoma originates in ... on by a known mutant, cancer-causing oncogene, say researchers ... San Francisco (UCSF). , Reporting in the Aug. 12 ... they have uncovered new origins for these tumors from ...
... Medical receives Governor,s 2008 Excellence in Exporting Award (,E-Award,), official state ... Lieutenant Governor Lee Fisher present award to CSZ Chairman of the ... ... 2008 -- Cincinnati Sub-Zero (CSZ) Medical, a division of CSZ Products, ...
... In one of the first examinations of PSA screening in ... Prostate Center finds that one-fifth of men under age 50 ... prostate cancer in the previous year, yet only one in ... in the previous year. , Overall, that,s pretty good ...
... LANSING, Mich. The health of people who never ... counterparts, according to new research that suggests the practice ... , Hui Liu, assistant professor of sociology at Michigan ... sociologists since the 1970s have emphasized that marriage benefits ...
Cached Medicine News:Health News:Home Care Agencies Staffing Challenge Solved With Caregiverlist.com 2Health News:Key to treating cancer may be finding its original cell 2Health News:Childhood brain tumor traced to normal stem cells gone bad 2Health News:Childhood brain tumor traced to normal stem cells gone bad 3Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 2Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 3Health News:Study finds more PSA screening awareness needed among high-risk groups 2Health News:Health and marriage: The times they are a changin' 2
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
The base of the staple is round and threaded to enable screwing onto the stapler. The base also has spikes. The legs of the staple are contoured to prevent the staple from backing out....
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
... ORTHOSET Radiopaque Bone Cement ... system: a sterile,ampule containing bone ... pack, and a sterile polyethylene ... a peelable pouch. The interiors ...
Medicine Products: